Not Yet RecruitingNot Applicable

Effect of SGLT2 Inhibitors on Anemic CKD Patients

Egypt60 participantsStarted 2026-01-01

Plain-language summary

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age more than 18 years * CKD stage 1\_4 * baseline hemoglobin 8.5 to 12.9 g/dl * stable anemia regimen for more than 8 weeks Exclusion Criteria: * dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

What they're measuring

hemoglobin level

Timeframe: 12 weeks

change in hemoglobin level

Timeframe: 12 weeks

Trial details

NCT IDNCT07334145

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07-01

Contact for this trial

Romany Naguib Mikhaeil, master

01274426883 romanynaguib977@gmail.com

View on ClinicalTrials.gov More Anemia in CKD Patients trials